肺癌患者红细胞内谷胱甘肽的含量与临床疗效的相关性

Determination of Glutathione in Erythrocyte in Patients with Pulmonary Carcinoma and Correlative to Therapeutic Effectiveness

目的与方法利用分光光度法,对33例肺癌患者及43例正常人红细胞内谷光甘肽（GSH）的含量进行测定,并与临床近期疗效的关系进行比较。结果肺癌患者治疗前后的GSH值与正常人之间有显著性差异（P＜0.05）。25例可观察近期疗效的患者中,有效者8例,其治疗前后的GSH及其与正常人之间无显著性差异（P＞0.1）;而治疗无效者17例,其治疗前后的GSH有显著性差异（P＜0.05）,与正常人之间有非常显著性差异（P＜0.01）。有转移与无转移患者治疗前GSH有显著性差异（P＜0.05）。且患者治疗前GSH高,临床治疗无效与治疗前GSH低临床治疗有效的总符合率为6667％（16／25）。结论肺癌患者GSH的高低与患者的有无转移及治疗预后密切相关,即GSH高治疗有效率低,GSH低治疗有效率高,预后好。

Purpose and Method The content of Glutathione (GSH) in erythrocyte was measured by spectrophotometer in 33 patients with pulmonary carcinoma and 43 normal volunteers and was studied with clinical therapeutic effectiveness. Results The results showed that there was very significant difference between patients and normal volunteers (P＜0. 05). Eight effective cases were among the 25 patients being observed the near clinical effectiveness,the.levels of GSH were 2. 003 ±0. 443 mg/gHb (before treatment) and 2.177±0. 443 mg/gHb (after treatment) respectively (p>0. 1). Levels of GSH in 17 ineffective cases were 2. 678± 0. 817 mg/gHb, and 3. 925± 1. 667 mg/gHb (P<0. 05). Furthermore there were 11.ineffective cases in patients with high level GSH before treatment and 5 effective cases in patients with low GSH level before treatment. Its coincidence rate was 66. 67%. Among all patients,the content of GSH before treatment was 2. 924± 0. 658 mg/gHb (23 cases with transferring) (P<0. 05). Conclusion It suggests that content of GSH may have important reference valve in patients with pulmonary carcinoma to confirm metastasis,therapeutic effectiveness and prognosis.